Aldeyra Therapeutics (ALDX) Net Income (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Net Income came in at -$3.5 million in Q1 2026, up 80.38% YoY from -$1.9 million in Q1 2025, and up 47.88% on a QoQ basis from -$6.6 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Net Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Net Income data on file, last reported at -$3.5 million in Q1 2026.
- Quarterly Net Income rose 80.38% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 52.23% YoY) and the FY2025 annual result came in at -$38.5 million, up 34.45% from the prior year.
- Net Income advanced to -$3.5 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$3.5 million in Q1 2026 to a low of -$41.5 million in Q1 2023.
- A 5-year average of -$16.0 million and a median of -$15.9 million in 2024 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 80.52% in 2024, down 263.5% in 2024.
- Tracing ALDX's Net Income over 5 years: stood at -$13.2 million in 2022, then surged by 66.67% to -$4.4 million in 2023, then slumped by 263.5% to -$15.9 million in 2024, then soared by 58.43% to -$6.6 million in 2025, then jumped by 47.88% to -$3.5 million in 2026.
- The last three Net Income figures came in at -$3.5 million (Q1 2026), -$6.6 million (Q4 2025), and -$14.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | -5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.43 Mn |
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.62 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -15.93 Mn |
| Sep 30, 2024 | -22.02 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -4.38 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -25.96 Mn |
| Mar 31, 2023 | -41.50 Mn |
| Dec 31, 2022 | -13.15 Mn |
| Sep 30, 2022 | -19.03 Mn |
| Jun 30, 2022 | -18.97 Mn |
| Mar 31, 2022 | -18.58 Mn |
| Dec 31, 2021 | -15.35 Mn |
| Sep 30, 2021 | -27.38 Mn |